United Kingdomroyaltypharma.com
Royalty Pharma plc is a publicly traded buyer of biopharmaceutical royalties and a funder of innovation in the life sciences sector.
Founded in 1996 and headquartered in New York, the company holds royalty interests in numerous marketed therapies and development-stage product candidates across areas including oncology, rare diseases, and immunology.
It is listed on Nasdaq under the ticker RPRX and has deployed substantial capital to acquire royalties since inception.
Recent activities include royalty acquisitions, R&D co-funding agreements, and the planned acquisition of its external manager.
Also known as RPRX.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
